Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00274313 · ClinicalTrials.gov registry record · Phase 1
Safety Study of Inhaled 552-02 in Cystic Fibrosis Patients
A Phase 1 study of Cystic Fibrosis, sponsored by Parion Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 15
- Study locations
NCT00274313: Completed Phase 1 study of Cystic Fibrosis, sponsored by Parion Sciences.
NCT00274313 is a Phase 1 study of Cystic Fibrosis that has completed, run by Parion Sciences. The registered enrollment target is 40 participants, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (78% lower). The trial reports 15 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00274313, a Phase 1 study of Cystic Fibrosis, has completed, sponsored by Parion Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 15
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and tolerability of a new inhaled sodium-channel blocker called 552-02 in teens and adults with cystic fibrosis. 552-02 will be inhaled once a day for 14 days using a nebulizer. A small subgroup of patients will donate blood samples for pharmacokinetic analysis to see how 552-02 is absorbed into the blood and eliminated after 14 days of treatment.
Conditions Studied
Interventions
- DRUG 552-02
Study Locations (15)
Pennsylvania
- Hershey Medical Center - Hershey
- Children's Hospital of Philadelphia - Philadelphia
- University of Pittsburgh - Pittsburgh
California
- University of California at San Diego - San Diego
- University of California at San Francisco Medical Center - San Francisco
Florida
- Nemours Children's Clinic - Orlando
- University of South Florida - Tampa
Colorado
- The Children's Hospital - Denver
Illinois
- Children's Memorial Hospital - Chicago
Nebraska
- University of Nebraska Medical Center - Omaha
New Jersey
- Morristown Memorial Hospital - Morristown
New York
- State University of New York Upstate - Syracuse
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2006-01 |
| Est. Completion | 2006-08 |
| Phase | Phase 1 |
What the finished NCT00274313 record still lists
NCT00274313 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (78% lower).
The record links to 1 condition, with Cystic Fibrosis appearing as the primary indexed condition, and to 1 intervention - of which 552-02 is the first listed.
NCT00274313 lists 15 locations in 11 states (Pennsylvania, California, Florida).
Frequently Asked Questions
What is clinical trial NCT00274313 about?
NCT00274313 is a clinical study titled "Safety Study of Inhaled 552-02 in Cystic Fibrosis Patients". The purpose of this study is to evaluate the safety and tolerability of a new inhaled sodium-channel blocker called 552-02 in teens and adults with cystic fibrosis. 552-02 will be inhaled once a day for 14 days using a nebulizer. A small subgroup of patients will donate blood samples for pharmacokin...
What is the current status of trial NCT00274313?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2006-01. Estimated completion is 2006-08.
What conditions does trial NCT00274313 study?
This clinical trial studies the following conditions: Cystic Fibrosis.
What interventions are being tested in trial NCT00274313?
The interventions under investigation include: 552-02 (DRUG).
Who is sponsoring clinical trial NCT00274313?
This trial is sponsored by Parion Sciences, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00274313 being conducted?
This trial has 15 study locations across California, Colorado, Florida, Illinois, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cystic Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00274313's enrollment target sits among peer trials
40 100th of 169 higher than 66 of 169 other Cystic Fibrosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cystic Fibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease
RECRUITING · Phase 1
-
A Study Assessing KB407 for the Treatment of Cystic Fibrosis
RECRUITING · Phase 1
-
Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy Participants
RECRUITING · Phase 1
-
A Phase 1/2 Trial of SP-101 for the Treatment of Cystic Fibrosis (CF)
RECRUITING · Phase 1
-
Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis
RECRUITING · Phase 1
-
A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia